Therefore, diagnostic use of FAP-based imaging might be recommended more as a complementary tool in later stages of prostate cancer together with PSMA and/or FDG PET as well as DOTATATE-PET for specifically targeting developing or established neuroendocrine de-differentiation. This evidence concerns the gene FOLH1 and prostate cancer.